Agilent 13. Feb. 2026 FDA Ovarian Cancer Nod Puts Focus On Agilent Valuation And Momentum - simplywall.st
Agilent 13. Feb. 2026 Agilent Technologies, Inc. (NYSE:A) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Agilent 13. Feb. 2026 Agilent Receives FDA Approval for Companion Diagnostic in Ovarian Cancer - Femtech Insider
Agilent 12. Feb. 2026 Agilent Technologies, Inc. (NYSE:A) to Issue $0.26 Quarterly Dividend - MarketBeat
Agilent 12. Feb. 2026 Agilent companion diagnostic lands FDA nod alongside Keytruda's latest cancer approval - Fierce Biotech
Agilent 11. Feb. 2026 Agilent Technologies (A) Declares $0.255 Quarterly Dividend; 0.8% Yield - StreetInsider
Agilent 11. Feb. 2026 Own Agilent stock by March 31? A $0.255 cash payout is coming in April - Stock Titan
Agilent 11. Feb. 2026 Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award - BioSpace
Agilent 11. Feb. 2026 Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award - Business Wire
Agilent 11. Feb. 2026 Madison Asset Management LLC Sells 14,089 Shares of Agilent Technologies, Inc. $A - MarketBeat
Agilent 11. Feb. 2026 Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC) - Business Wire
Agilent 11. Feb. 2026 FDA approves first immunotherapy-linked test to guide ovarian cancer care - Stock Titan
Agilent 11. Feb. 2026 Gas Chromatography Detector Market Is Going to Boom |• Agilent Technologies • Thermo Fisher Scientific - openPR.com